hydromorphone-3-glucuronide: major metabolite of hydromorphone [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 20727855 |
| MeSH ID | M0246873 |
| Synonym |
|---|
| hydromorphone-3-glucuronide |
| 3,4,5-trihydroxy-6-[(3-methyl-7-oxo-1,2,4,4a,5,6,7a,13-octahydro-4,12-methanobenzofuro[3,2-e]isoquinolin-9-yl)oxy]oxane-2-carboxylic acid |
| Excerpt | Reference | Relevance |
|---|---|---|
| "mL-1, P = NS, Cmax 17." | ( Steady-state pharmacokinetics of hydromorphone and hydromorphone-3-glucuronide in cancer patients after immediate and controlled-release hydromorphone. Babul, N; Darke, AC; Dhaliwal, HS; Hagen, N; Harsanyi, Z; Thirlwell, MP, 1995) | 0.29 |
| " The present assay was applied to a pharmacokinetic study in rat after intraperitoneal administration of hydromorphone." | ( LC-MS-MS analysis of hydromorphone and hydromorphone metabolites with application to a pharmacokinetic study in the male Sprague-Dawley rat. McErlane, KM; Ong, MC; Zheng, M, 2002) | 0.31 |
| "To describe the pharmacokinetics of hydromorphone (HM) and its primary metabolite hydromorphone-3-glucuronide (H3G) both on and off dialysis in relation to the pharmacodynamic measurements of pain." | ( Pain management in chronic kidney disease: the pharmacokinetics and pharmacodynamics of hydromorphone and hydromorphone-3-glucuronide in hemodialysis patients. Davison, SN; Mayo, PR, ) | 0.13 |
| Excerpt | Relevance | Reference |
|---|---|---|
| " The authors conclude that CR hydromorphone provides a pharmacokinetic profile consistent with 12 hourly dosing and that at steady state, oral hydromorphone is extensively metabolized to H3G, although the pharmacologic activity of this metabolite remains unknown." | ( Steady-state pharmacokinetics of hydromorphone and hydromorphone-3-glucuronide in cancer patients after immediate and controlled-release hydromorphone. Babul, N; Darke, AC; Dhaliwal, HS; Hagen, N; Harsanyi, Z; Thirlwell, MP, 1995) | 0.29 |
| " Thus, our data clearly imply that if H3G crosses the BBB with equivalent efficiency to M3G, then the myoclonus, allodynia and seizures observed in some patients dosed chronically with large systemic doses of HMOR, are almost certainly due to the accumulation of sufficient H3G in the central nervous system, to evoke behavioural excitation." | ( Hydromorphone-3-glucuronide: a more potent neuro-excitant than its structural analogue, morphine-3-glucuronide. Mather, LE; Smith, MT; Wright, AW, 2001) | 0.31 |
| " HM resulted in > 65 percent reduction in pain over dosing intervals." | ( Pain management in chronic kidney disease: the pharmacokinetics and pharmacodynamics of hydromorphone and hydromorphone-3-glucuronide in hemodialysis patients. Davison, SN; Mayo, PR, ) | 0.13 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (15.38) | 18.2507 |
| 2000's | 4 (30.77) | 29.6817 |
| 2010's | 5 (38.46) | 24.3611 |
| 2020's | 2 (15.38) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 5 (33.33%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 1 (6.67%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 9 (60.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||